Alpha Cognition (OTC:ACOGF) Sets New 12-Month High – Time to Buy?

Shares of Alpha Cognition Inc. (OTC:ACOGF) hit a new 52-week high during trading on Tuesday . The company traded as high as C$8.75 and last traded at C$8.75, with a volume of 18 shares trading hands. The stock had previously closed at C$8.75.

Analyst Upgrades and Downgrades

Separately, Raymond James upgraded shares of Alpha Cognition from a “hold” rating to a “moderate buy” rating in a research report on Monday, July 15th.

Alpha Cognition Stock Performance

The stock’s 50-day simple moving average is C$0.40 and its 200-day simple moving average is C$0.48. The firm has a market capitalization of C$1.32 billion, a P/E ratio of -72.91 and a beta of 2.80.

Alpha Cognition (OTC:ACOGF) last issued its quarterly earnings results on Monday, August 12th. The company reported C($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of C($0.04) by C$0.03. On average, equities research analysts expect that Alpha Cognition Inc. will post -0.19 EPS for the current year.

About Alpha Cognition

Alpha Cognition Inc, a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.